Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Director Bros. Advisors Lp Baker purchased 660,779 shares of the business’s stock in a transaction on Thursday, June 15th. The stock was bought at an average cost of $117.33 per share, with a total value of $77,529,200.07. The purchase was disclosed in a filing with the SEC, which is available at this link.
Bros. Advisors Lp Baker also recently made the following trade(s):
- On Wednesday, June 14th, Bros. Advisors Lp Baker purchased 1,348,955 shares of Alexion Pharmaceuticals stock. The stock was bought at an average cost of $116.32 per share, with a total value of $156,910,445.60.
Shares of Alexion Pharmaceuticals, Inc. (ALXN) traded down 3.39% on Friday, reaching $113.98. 4,622,346 shares of the company’s stock traded hands. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $145.41. The stock has a 50-day moving average of $113.83 and a 200 day moving average of $122.49. The firm has a market cap of $25.59 billion, a P/E ratio of 54.30 and a beta of 1.45. Alexion Pharmaceuticals also was the target of unusually large options trading activity on Wednesday. Investors acquired 1,630 call options on the company. This is an increase of approximately 549% compared to the average daily volume of 251 call options.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.38 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.33. Alexion Pharmaceuticals had a net margin of 14.52% and a return on equity of 11.72%. The business had revenue of $870 million during the quarter, compared to the consensus estimate of $826.63 million. During the same quarter last year, the firm earned $1.11 earnings per share. Alexion Pharmaceuticals’s quarterly revenue was up 24.3% on a year-over-year basis. On average, equities research analysts expect that Alexion Pharmaceuticals, Inc. will post $5.31 earnings per share for the current year.
WARNING: “Bros. Advisors Lp Baker Buys 660,779 Shares of Alexion Pharmaceuticals, Inc. (ALXN) Stock” was first posted by sleekmoney and is owned by of sleekmoney. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://sleekmoney.com/bros-advisors-lp-baker-buys-660779-shares-of-alexion-pharmaceuticals-inc-alxn-stock/1916415.html.
Institutional investors have recently made changes to their positions in the company. Advantage Investment Management LLC purchased a new position in shares of Alexion Pharmaceuticals during the fourth quarter worth $101,000. Guardian Life Insurance Co. of America increased its position in shares of Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 6 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Alexion Pharmaceuticals during the first quarter worth $111,000. Independent Portfolio Consultants Inc. increased its position in shares of Alexion Pharmaceuticals by 46.9% in the first quarter. Independent Portfolio Consultants Inc. now owns 1,065 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 340 shares in the last quarter. Finally, FUKOKU MUTUAL LIFE INSURANCE Co increased its position in shares of Alexion Pharmaceuticals by 10.0% in the first quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,100 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 100 shares in the last quarter. 94.38% of the stock is owned by institutional investors and hedge funds.
ALXN has been the subject of a number of research reports. Barclays PLC reaffirmed an “overweight” rating and issued a $155.00 price objective on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. Deutsche Bank AG cut their price objective on shares of Alexion Pharmaceuticals from $160.00 to $153.00 and set a “buy” rating for the company in a research note on Thursday, May 25th. Raymond James Financial, Inc. reaffirmed a “strong-buy” rating and issued a $176.00 price objective on shares of Alexion Pharmaceuticals in a research note on Tuesday, May 9th. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and issued a $158.00 price objective on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Thursday, February 16th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $161.38.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/bros-advisors-lp-baker-buys-660779-shares-of-alexion-pharmaceuticals-inc-alxn-stock/1916415.html
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.